Research graph
References from Clinical and economic outcomes of adding [18F]FES PET/CT in estrogen receptor status identification in metastatic and recurrent breast cancer in the US. Local targets link to admitted publications; unresolved targets remain external evidence.
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
10.3322/caac.21660 · 2021 · External reference
Between-patient and within-patient (site-to-site) variability in estrogen receptor binding, measured in vivo by 18F-fluoroestradiol PET.
10.2967/jnumed.111.091439 · 2011 · External reference
Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications.
10.1634/theoncologist.2019-0967 · 2020 · External reference
Role of estrogen receptor signaling in breast cancer metastasis
10.1155/2012/654698 · 2012 · External reference
Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
10.1200/jco.19.02309 · 2020 · External reference
Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.
10.1158/1078-0432.ccr-16-0362 · 2017 · External reference
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.
10.1016/s0140-6736(11)60993-8 · 2011 · External reference
Receptor conversion in distant breast cancer metastases
10.1186/bcr2645 · 2010 · External reference
Discordance in hormone receptor status among primary, metastatic, and second primary breast cancers: biological difference or misclassification?
10.1634/theoncologist.2013-0427 · 2014 · External reference
Breast cancer heterogeneity
10.3390/diagnostics11091555 · 2021 · External reference
When to order a biopsy to characterise a metastatic relapse in breast cancer
2012 · External reference
Deciding site of biopsy at metastatic relapse.
10.1177/1758834014551935 · 2014 · External reference
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
10.1016/j.annonc.2021.09.019 · 2021 · External reference
Incidence, causes, and implications of unsuccessful calciication retrieval at stereotactic breast biopsy—5 years’ experience.
2009 · External reference
Intratumoral heterogeneity as a source of discordance in breast cancer biomarker classification
10.1186/s13058-016-0725-1 · 2016 · External reference
Discordance in ERα, PR and HER2 receptor status across different distant breast cancer metastases within the same patient
10.1093/annonc/mdt390 · 2013 · External reference
Summary: Appropriate Use Criteria for Estrogen Receptor-Targeted PET Imaging with 16α-(18)F-Fluoro-17β-Fluoroestradiol.
10.2967/jnumed.123.265420 · 2023 · External reference
The influence of receptor expression and clinical subtypes on baseline [18F]FDG uptake in breast cancer: systematic review and meta-analysis
10.1186/s13550-023-00953-y · 2023 · External reference
Bone metastases from breast cancer: associations between morphologic CT patterns and glycolytic activity on PET and bone scintigraphy as well as explorative search for influential factors
10.1007/s12149-017-1202-3 · 2017 · External reference
Imaging diagnosis of metastatic breast cancer
10.1186/s13244-020-00885-4 · 2020 · External reference
Limitations and Pitfalls of FDG-PET/CT in Infection and Inflammation.
10.1053/j.semnuclmed.2021.06.008 · 2021 · External reference
16alpha-18F-fluoro-17beta-Fluoroestradiol (FES): clinical applications for patients with breast cancer
10.1053/j.semnuclmed.2022.03.002 · 2022 · External reference
Head-to-Head Evaluation of (18)F-FES and (18)F-FDG PET/CT in Metastatic Invasive Lobular Breast Cancer.
10.2967/jnumed.120.247882 · 2021 · External reference
Value of (18)F-FES PET in Solving Clinical Dilemmas in Breast Cancer Patients: A Retrospective Study.
10.2967/jnumed.120.256826 · 2021 · External reference
Diagnostic accuracy and safety of 16α-[(18)F]fluoro-17β-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study
10.1016/s1470-2045(18)30936-7 · 2019 · External reference
Clinical validity of 16α-[(18)F]fluoro-17β-estradiol positron emission tomography/computed tomography to assess estrogen receptor status in newly diagnosed metastatic breast cancer
10.1200/jco.22.00400 · 2022 · External reference
Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition
10.1016/j.ejca.2019.10.024 · 2020 · External reference
Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research.
10.1007/s10549-014-3145-x · 2014 · External reference
Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups
10.1038/s41586-019-1007-8 · 2019 · External reference
New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients
10.1186/s12885-021-08219-3 · 2021 · External reference
The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer
10.1186/s12885-019-6311-z · 2019 · External reference
Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options
10.1186/s12885-018-4101-7 · 2018 · External reference
Safety and Effectiveness of F-18 Fluoroestradiol Positron Emission Tomography/Computed Tomography: a Systematic Review and Meta-analysis.
10.3346/jkms.2021.36.e271 · 2021 · External reference
Concordance between core needle biopsy and surgical specimen for oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 status in breast cancer
10.11622/smedj.2016062 · 2017 · External reference
Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer
10.1200/jco.2010.33.5232 · 2012 · External reference
Percutaneous CT-guided biopsy of the musculoskeletal system: results of 2027 cases.
10.1016/j.ejrad.2010.06.055 · 2011 · External reference
An Audit of Failed Immunohistochemical Slides in a Clinical Laboratory: The Role of On-Slide Controls.
10.1097/pai.0000000000000305 · 2017 · External reference
Lapatinib plus chemotherapy or endocrine therapy (CET) versus CET alone in the treatment of HER-2-overexpressing locally advanced or metastatic breast cancer: systematic review and meta-analysis.
10.2147/ce.s50474 · 2013 · External reference
Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
10.1007/s10549-019-05190-3 · 2019 · External reference
Economic burden related to chemotherapy-related adverse events in patients with metastatic breast cancer in an integrated health care system
2016 · External reference
Cost-Effectiveness of Ribociclib for Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
10.2147/cmar.s284556 · 2020 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer
10.3111/13696998.2016.1151431 · 2016 · External reference
Health state utilities for metastatic breast cancer
10.1038/sj.bjc.6603326 · 2006 · External reference
Studies on the synthesis of 16a-[18F]fluoroestradiol
1996 · External reference
Recommendations and Technical Aspects of 16alpha-[18F]Fluoro-17beta-Estradiol PET to Image the Estrogen Receptor In Vivo
10.1097/rlu.0000000000001347 · 2016 · External reference
EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies
10.1007/s00259-017-3740-2 · 2017 · External reference
NCCN Guidelines: Breast Cancer 2023 [cited 2023 August 14].
External reference
Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer
2021 · External reference
Costs of the dfiagnostic workup for lung cancer: a medicare claims analysis
10.1016/j.ijrobp.2014.08.142 · 2014 · External reference
Cost-effectiveness analysis of everolimus plus exemestane versus exemestane alone for treatment of hormone receptor positive metastatic breast cancer
10.1007/s10549-014-3042-3 · 2014 · External reference
Unresolved reference
2021 · External reference
Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States
10.1080/14737167.2020.1804871 · 2021 · External reference
Molecular imaging with positron emission tomography and computed tomography (PET/CT) for selecting first-line targeted treatment in metastatic breast cancer: a cost-effectiveness study.
10.18632/oncotarget.24869 · 2018 · External reference
Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma
10.1038/s41523-021-00233-9 · 2021 · External reference
Breast MRI: guidelines from the European Society of Breast Imaging.
2008 · External reference
Digital breast tomosynthesis as an adjunct to digital mammography for detecting and characterising invasive lobular cancers: a multi-reader study.
10.1016/j.crad.2016.04.004 · 2016 · External reference
Pre-operative and intra-operative detection of axillary lymph node metastases in 108 patients with invasive lobular breast cancer undergoing mastectomy
10.1186/s12885-018-4062-x · 2018 · External reference
Evaluation of tumour heterogeneity by (18)F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment.
10.1186/s13058-022-01555-7 · 2022 · External reference
Chemotherapy shows a better efficacy than endocrine therapy in metastatic breast cancer patients with a heterogeneous estrogen receptor expression assessed by (18)F-FES PET.
10.3390/cancers14143531 · 2022 · External reference
